The finalisation of Proxima 4's development phase opens the way for its commercialisation in Europe, with CE Marking expected mid-2016. The experience gained with Proxima 3 has provided valuable insights that should improve market traction. A launch employing the in-house sales team is expected before year-end but exploiting Proxima 4's potential will require a well-placed existing player. The identification of a suitable marketing partner is a critical next step, with initial discussions underway. Our three phase DCF- based model suggests a valuation of £14.4m, equivalent to 10.2p per share.
25 Feb 2016
Worthy of further evaluation
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Worthy of further evaluation
Sphere Medical Holding (SPHR:LON) | 0 0 0.0% | Mkt Cap: 0.037m
- Published:
25 Feb 2016 -
Author:
Franc Gregori -
Pages:
15
The finalisation of Proxima 4's development phase opens the way for its commercialisation in Europe, with CE Marking expected mid-2016. The experience gained with Proxima 3 has provided valuable insights that should improve market traction. A launch employing the in-house sales team is expected before year-end but exploiting Proxima 4's potential will require a well-placed existing player. The identification of a suitable marketing partner is a critical next step, with initial discussions underway. Our three phase DCF- based model suggests a valuation of £14.4m, equivalent to 10.2p per share.